ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals develops and commercializes therapeutics based on RNA interference (RNAi) technology, an approach that silences disease-causing genes. The company's marketed products include ONPATTRO and AMVUTTRA for hereditary transthyretin amyloidosis, Leqvio for hypercholesterolemia, Qfitlia for hemophilia, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. Beyond these approved drugs, Alnylam maintains an extensive pipeline with multiple candidates in Phase 3 trials targeting conditions such as ATTR amyloidosis, hypertension, myasthenia gravis, and hepatitis D virus infection.

The company's pipeline extends into earlier-stage development with Phase 2 programs addressing metabolic dysfunction-associated steatohepatitis, diabetic kidney disease, type 2 diabetes, and cerebral amyloid angiopathy. Phase 1 assets span a broader range of indications including obesity, neurological diseases such as Huntington's and Parkinson's, amyotrophic lateral sclerosis, and hepatocellular carcinoma.

Alnylam operates with approximately 2,500 full-time employees and maintains a geographic footprint across the United States, Europe, and international markets. The company has established collaborations with major pharmaceutical and biotechnology firms including Regeneron, Roche, Sanofi, Novartis, and Ionis Pharmaceuticals. Founded in 2002, the company is headquartered in Cambridge, Massachusetts.